Oncologic outcomes of patients with Merkel Cell Carcinoma (MCC): A multi-institutional cohort study

Bleicher, Josh; Asare, Elliot A.; Flores, Shadai; Bowles, Tawnya L.; Bowen, Glen M.; Hyngstrom, John

doi:10.1016/j.amjsurg.2020.08.013

Cited by 6 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bleicher et al retrospectively reviewed and reported the medical history of 102 MCC patients in the USA, and their results demonstrated that tumor stage (P < 0.01) and advanced age at diagnosis (P < 0.01) were both risk factors for tumor recurrence and decreased OS time(25). Additionally, as shown in our multivariate Cox regression analysis for all enrolled patients, the use of CT was significantly correlated with decreased OS (P…”

supporting

confidence: 56%

Prognostic Value of Radiotherapy and Chemotherapy in Stage I–III Merkel Cell Carcinoma

Yang

Ding

et al. 2022

Front. Med.

View full text Add to dashboard Cite

PurposeMerkel cell carcinoma (MCC) is a highly malignant cancer associated with dismal survival outcomes. Surgery is the cornerstone for the management of MCC, but the benefit of radiotherapy (RT) and chemotherapy (CT) is still controversial. We aimed to investigate the prognostic value of RT and CT in the management of stage I-III MCC patients using the Surveillance, Epidemiology, and End Results (SEER) database.MethodsPatients with a histopathological diagnosis of MCC between 2010 and 2016 were included. The primary endpoint of this study was overall survival (OS). The prognostic significance for OS was analyzed by Cox proportional hazard regression model.ResultsA total of 1,691 patients were identified in the SEER database. Over half of the patients had received RT (56.7%), and 9.8% of the patients were documented to have received CT. The median OS for the entire cohort was 66.0 months, and the 5-year OS rate was 53.8%. In the multivariate analysis, receiving RT was associated with significantly improved OS (P < 0.001), while receiving CT significantly negatively impacted OS (P = 0.010). In stage III patients who underwent treatment based on surgical resection, RT was still demonstrated to be a positive factor (P = 0.002), while CT had no significant association with OS in the univariate analysis (P = 0.295).ConclusionsThe current data in the SEER database are consistent with earlier studies supporting the benefit of adjuvant RT for stage I-III MCC patients, but caution should be taken regarding the routine use of CT. For stage III MCC patients, the value of adjuvant CT needs to be confirmed in future studies.

show abstract

supporting

confidence: 56%

Prognostic Value of Radiotherapy and Chemotherapy in Stage I–III Merkel Cell Carcinoma

Yang

Ding

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…[5][6][7] Up to 37% of patients present with nodal disease, which is associated with a five-year OS of 26.8-46.0%. [5,6,8] The mainstay of treatment for MCC consists of locoregional surgery. A wide local excision (WLE) of the primary tumor, accompanied by a sentinel lymph node biopsy (SN) in clinically nodenegative disease, is recommended.…”

Section: Introductionmentioning

confidence: 99%

Postoperative radiotherapy in stage I–III Merkel cell carcinoma

Levy

Blankenstein

Grünhagen

et al. 2022

Radiotherapy and Oncology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…Merkel cell carcinoma (MCC) is a rare type of skin cancer with a high tendency to metastasize. At primary diagnosis, nodal metastases are present in 15%–32% of all MCC patients, and 7%–8% present with metastases at distant sites 1–4 . The overall survival (OS) decreases with increasing tumor stage, with an expected 5‐year OS of 51% for localized, 35% for nodal, and 14% for distant disease according to the American Joint Committee on Cancer criteria (AJCC) eighth edition staging system 1 .…”

Section: Introductionmentioning

confidence: 99%

“…At primary diagnosis, nodal metastases are present in 15%-32% of all MCC patients, and 7%-8% present with metastases at distant sites. [1][2][3][4] The overall survival (OS) decreases with increasing tumor stage, with an expected 5-year OS of 51% for localized, 35% for nodal, and 14% for distant disease according to the American Joint Committee on Cancer criteria (AJCC) eighth edition staging system. 1 Importantly, since MCC is a disease often found in elderly and frail, the disease-specific or MCC-specific survival does not correlate with overall survival.…”

Section: Introductionmentioning

confidence: 99%

Baseline ultrasound and FDG‐PET/CT imaging in Merkel cell carcinoma

Zijlker

Bakker

Hiel

et al. 2022

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background Merkel cell carcinoma (MCC) is a cutaneous tumor with a high tendency to metastasize, and a significant proportion of patients have metastases at first presentation. This study aims to determine the value of baseline ultrasound (US) and 18fluorodeoxyglucose‐positron emission tomography/computed tomography (18FDG‐PET/CT) imaging in both patients with clinically localized MCC (Stage I/II) and patients who present with palpable lymph nodes (Stage III). Methods This retrospective cohort included 135 MCC patients who underwent baseline US (with fine needle aspiration cytology (FNAC)) and/or FDG‐PET/CT imaging between 2015 and 2021. Results Of the 104 patients with clinically localized disease, 48% were upstaged to Stage III and 3% to Stage IV by imaging or sentinel lymph node biopsy (SLNB). FDG‐PET/CT imaging identified regional metastases in 23%, while US with FNAC identified regional metastases in 19%. SLNB was performed in 56 patients, of whom 57% were upstaged to Stage III. Of the 31 patients who presented with palpable lymph nodes, 16% were upstaged to Stage IV by FDG‐PET/CT imaging. Conclusion Baseline imaging frequently upstages Stage I/II MCC patients to Stage III, both by US and FDG‐PET/CT, Stage IV disease is rarely identified. Patients who present with palpable nodes are frequently upstaged to Stage IV by FDG‐PET/CT imaging.

show abstract

Oncologic outcomes of patients with Merkel Cell Carcinoma (MCC): A multi-institutional cohort study

Cited by 6 publications

References 34 publications

Prognostic Value of Radiotherapy and Chemotherapy in Stage I–III Merkel Cell Carcinoma

Prognostic Value of Radiotherapy and Chemotherapy in Stage I–III Merkel Cell Carcinoma

Postoperative radiotherapy in stage I–III Merkel cell carcinoma

Baseline ultrasound and FDG‐PET/CT imaging in Merkel cell carcinoma

Contact Info

Product

Resources

About